Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors
Carolina Reduzzi(Cornell University), Massimo Cristofanilli(Cornell University), Eleonora Nicolò(Cornell University), Umberto Malapelle(Federico II University Hospital), Diego de Miguel‐Pérez(Mount Sinai Health System), Nicola Fusco(University of Milan), David R. Gandara(University of California, Davis), Angelo Dipasquale(IRCCS Humanitas Research Hospital), Eloísa Jantus‐Lewintre(Hospital General Universitario De Valencia), María José Serrano(Instituto de Investigación Biosanitaria de Granada), Mohamed A. Gouda(The University of Texas MD Anderson Cancer Center), Christian Rolfo(Icahn School of Medicine at Mount Sinai), Pashtoon Murtaza Kasi(Cornell University), Erick Figueiredo Saldanha(Princess Margaret Cancer Centre), Konstantinos Venetis(European Institute of Oncology), Ana Ortega-Franco(The Christie NHS Foundation Trust), Surbhi Singhal(International Society of Nephrology)
Cited by 22
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Colorectal cancer
|The Lancet|2019|5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k